Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/50498
Title: Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.
Authors: Song Y.;Zhou K.;Zou D.;Li D.;Hu J.;Yang H.;Zhang H.;Ji J.;Xu W.;Jin J.;Lv F.;Feng R.;Gao S.;Zhou D.;Tam C.S.;Simpson D.;Wang M.;Phillips T.J.;Opat S. ;Fang C.;Sun S.;Zhu J.
Monash Health Department(s): Haematology
Institution: (Song, Zhu) Peking University Cancer Hospital and Institute, Beijing, China
(Zhou) Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China
(Zou) Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
(Li) Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
(Hu) Fujian Medical University Union Hospital, Fuzhou, China
(Yang) The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China
(Zhang) Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
(Ji) West China Hospital of Sichuan University, Chengdu, China
(Xu) The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
(Jin) The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China
(Lv) Fudan University Shanghai Cancer Center, Shanghai, China
(Feng) Nanfang Hospital of Southern Medical University, Guangzhou, China
(Gao) The First Hospital of Jilin University, Changchun, China
(Zhou) Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
(Tam) Peter MacCallum Cancer Centre, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia
(Simpson) North Shore Hospital, Auckland, New Zealand
(Wang) The University of Texas MD Anderson Cancer Center, Houston, TX, United States
(Phillips) University of Michigan, Ann Arbor, MI, United States
(Opat) Monash Health, Monash University, Clayton, VIC, Australia
(Fang, Sun) BeiGene (Beijing) Co., Ltd., Beijing, China
Issue Date: 17-Oct-2023
Copyright year: 2023
Publisher: John Wiley and Sons Inc
Place of publication: United Kingdom
Publication information: Cancer Medicine. 12(18) (pp 18643-18653), 2023. Date of Publication: September 2023.
Journal: Cancer Medicine
Abstract: Background: We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second-line versus later-line. Here, we present an updated pooled analysis with a longer follow-up of 35.2 months. Method(s): Data were pooled from two studies-BGB-3111-AU-003 (NCT02343120) and BGB-3111-206 (NCT03206970) of zanubrutinib in R/R MCL. The patients were divided into two groups based on the treatment line of zanubrutinib: the second-line and the later-line group. The inverse propensity score weighting method was used to balance the baseline covariates between the groups. The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), PFS, and OS rates, objective response rate (ORR), duration of response (DOR), and safety. Result(s): Among 112 pooled patients, 41 (36.6%) patients received zanubrutinib as second-line and 71 (63.4%) patients as later-line therapy. After weighting, OS was significantly improved in the second-line versus later-line group (HR, 0.459 [95% CI: 0.215, 0.98]; p = 0.044) with median OS not estimable in both groups. The PFS was similar between the two groups (HR, 0.78 [95% CI: 0.443, 1.373]; p = 0.389) but with numerically longer median PFS in the second-line versus later-line group (27.8 vs. 22.1 months). ORR was numerically higher in the second-line versus later-line (88.6% vs. 85.7%), and DOR was similar between the two groups (25.2 vs. 25.1 months). Zanubrutinib showed a similar safety profile in both groups. Conclusion(s): Zanubrutinib in second-line treatment was associated with significantly improved OS compared with later-line treatment of R/R MCL.Copyright © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
DOI: http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1002/cam4.6473
PubMed URL: 37705497 [https://www.ncbi.nlm.nih.gov/pubmed/?term=37705497]
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/50498
Type: Article
Subjects: atrial fibrillation
bleeding
diarrhea
heart atrium flutter
hypertension
monotherapy
Appears in Collections:Articles

Show full item record

Page view(s)

48
checked on Mar 15, 2025

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.